

Laura M De Castro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11401704/publications.pdf>

Version: 2024-02-01

39
papers

1,885
citations

516710

16
h-index

477307

29
g-index

39
all docs

39
docs citations

39
times ranked

2030
citing authors

#	ARTICLE	IF	CITATIONS
1	<p>Development of a Severity Classification System for Sickle Cell Disease</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 625-633.	1.9	12
2	Real World Evidence of Prescription Patterns and Effect of Oxbrtya (voxelotor) for Patients with Sickle Cell Disease. Blood, 2020, 136, 31-32.	1.4	2
3	Associations between hematology/oncology fellowsâ€™ training and mentorship experiences and hematology-only career plans. Blood Advances, 2019, 3, 3278-3286.	5.2	17
4	Healthcare Utilization Patterns and Health Quality Indicators in Sickle Cell Disease Patients Transitioning from Pediatric to Adulthood. Blood, 2018, 132, 3513-3513.	1.4	0
5	The Conundrum of Hydroxyurea Use and Health Care Utilization in Sickle Cell Disease. Blood, 2018, 132, 2282-2282.	1.4	0
6	Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Advances, 2017, 1, 1983-1992.	5.2	66
7	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 207-211.	2.0	97
8	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 2015, 125, 2656-2664.	1.4	178
9	Factors associated with survival in a contemporary adult sickle cell disease cohort. American Journal of Hematology, 2014, 89, 530-535.	4.1	235
10	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
11	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood, 2013, 122, 776-776.	1.4	7
12	Sickle Cell Crisis: Safety Of a High-Dose Opioid Protocol In The Emergency Department. Blood, 2013, 122, 5579-5579.	1.4	0
13	Effect of Propranolol as Antiadhesive Therapy in Sickle Cell Disease. Clinical and Translational Science, 2012, 5, 437-444.	3.1	40
14	Genetic and Epigenetic Regulation of the Gamma Globin Locus Is Associated with Fetal Hemoglobin Levels and Frequency of Pain in Sickle Cell Disease. Blood, 2012, 120, 3230-3230.	1.4	0
15	Information Technology Use by Patients with Hemoglobinopathies. Blood, 2012, 120, 4698-4698.	1.4	0
16	<i>MYH9</i> and <i>APOL1</i> are both associated with sickle cell disease nephropathy. British Journal of Haematology, 2011, 155, 386-394.	2.5	139
17	Living with sickle cell disease: traversing â€™raceâ€™ and identity. Ethnicity and Health, 2011, 16, 389-404.	2.5	19
18	Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. American Journal of Hematology, 2010, 85, 36-40.	4.1	167

#	ARTICLE	IF	CITATIONS
19	Clinical and Sociodemographic Factors Predict Coping Styles Among Adults With Sickle Cell Disease. Journal of the National Medical Association, 2010, 102, 1045-1049.	0.8	8
20	GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease. Blood, 2010, 116, 1632-1632.	1.4	6
21	Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion In Sickle Cell Disease: Results From a Phase 1/2 Study. Blood, 2010, 116, 262-262.	1.4	4
22	A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease. Blood, 2010, 116, 3221-3221.	1.4	4
23	Advance Care Planning In Adults with Sickle Cell Disease (SCD). Blood, 2010, 116, 391-391.	1.4	1
24	Genetic Variation In MYH9 Is Associated with Sickle Cell Disease Nephropathy. Blood, 2010, 116, 1648-1648.	1.4	0
25	Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. American Journal of Hematology, 2008, 83, 19-25.	4.1	244
26	β ₂ -Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion. British Journal of Haematology, 2008, 141, 105-108.	2.5	30
27	Surgical and Obstetric Outcomes in Adults with Sickle Cell Disease. American Journal of Medicine, 2008, 121, 916-921.	1.5	48
28	Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood, 2008, 111, 5721-5726.	1.4	66
29	Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood, 2008, 111, 3991-3997.	1.4	193
30	The Effects of Chronic Opiates Pain Therapy in Sickle Cell Anemia.. Blood, 2007, 110, 3404-3404.	1.4	0
31	The Relationship of Opiate Analgesia to Quality of Life in an Adult Sickle Cell Population.. Blood, 2007, 110, 2261-2261.	1.4	0
32	Effect of Single Dose In Vivo Propranolol Therapy on In Vitro Adhesion of Human SS RBC.. Blood, 2006, 108, 1234-1234.	1.4	4
33	Current Prevalence of Specific Clinical Outcomes in Adult Patients with Hb SS or Hb Sβ ⁰ Thalassemia.. Blood, 2006, 108, 1201-1201.	1.4	1
34	A brief review of the pathophysiology, associated pain, and psychosocial issues in sickle cell disease. International Journal of Behavioral Medicine, 2005, 12, 171-179.	1.7	110
35	Clinical and Genetic Profiles of the Aging Sickle Cell Patient.. Blood, 2005, 106, 75-75.	1.4	5
36	Priapism in SCD: Clinical and Genetic Correlations.. Blood, 2005, 106, 3174-3174.	1.4	0

#	ARTICLE	IF	CITATIONS
37	B-CAM/CD44 expression and the role of B-CAM/CD44 activation in binding of low- and high-density red cells to laminin in sickle cell disease. <i>American Journal of Hematology</i> , 2004, 75, 63-72.	4.1	32
38	Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW- α 1 ^v 3 interactions. <i>Blood</i> , 2004, 104, 3774-3781.	1.4	135
39	Pulmonary Hypertension in SS, SC and S β ⁰ Thalassemia: Prevalence, Associated Clinical Syndromes, and Mortality.. <i>Blood</i> , 2004, 104, 1663-1663.	1.4	13